BeiGene Cash Flow from Financial Activities 2014-2024 | ONC
BeiGene annual/quarterly cash flow from financial activities history and growth rate from 2014 to 2024. Cash flow from financial activities can be defined as the net amount of cash transactions used in funding activities
- BeiGene cash flow from financial activities for the quarter ending September 30, 2024 was $0.198B, a 185.14% increase year-over-year.
- BeiGene cash flow from financial activities for the twelve months ending September 30, 2024 was $0.962B, a 444.14% increase year-over-year.
- BeiGene annual cash flow from financial activities for 2023 was $0.416B, a 2295.34% decline from 2022.
- BeiGene annual cash flow from financial activities for 2022 was $-0.019B, a 100.52% decline from 2021.
- BeiGene annual cash flow from financial activities for 2021 was $3.637B, a 30.1% decline from 2020.
BeiGene Annual Cash Flow Financial
(Millions of US $) |
| 2023 |
$416 |
| 2022 |
$-19 |
| 2021 |
$3,637 |
| 2020 |
$5,203 |
| 2019 |
$86 |
| 2018 |
$1,691 |
| 2017 |
$490 |
| 2016 |
$381 |
| 2015 |
$103 |
| 2014 |
$52 |
| 2013 |
$-0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
